MARKET

RUBY

RUBY

Rubius Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.48
+0.03
+0.47%
Closed 16:14 06/01 EDT
OPEN
6.49
PREV CLOSE
6.45
HIGH
6.57
LOW
6.27
VOLUME
144.13K
TURNOVER
--
52 WEEK HIGH
16.16
52 WEEK LOW
3.350
MARKET CAP
521.18M
P/E (TTM)
-2.8688
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average RUBY stock price target is 10.00 with a high estimate of 28.00 and a low estimate of 3.000.

EPS

RUBY News

More
Hedge Funds Are Selling Rubius Therapeutics, Inc. (RUBY)
Insider Monkey · 19h ago
Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-Partner and CEO of Cellarity
PR Newswire · 4d ago
Rubius Therapeutics to Present at Jefferies Virtual 2020 Healthcare Conference
CAMBRIDGE, Mass., May 26, 2020 -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create.
GlobeNewswire · 6d ago
Rubius Therapeutics to Present Preclinical Data for RTX-321, a Red Cell Therapeutic Oncology Product Candidate for HPV-Positive Cancers at the American Association of Cancer Research Annual Meeting
GlobeNewswire · 05/15 13:00
Rubius Therapeutics Highlights Preclinical Data for RTX-321, a Red Cell Therapeutic Oncology Product Candidate for HPV-Positive Cancers, at the American Society of Gene & Cell Therapy 23rd Annual Meeting
GlobeNewswire · 05/12 11:00
Rubius Therapeutics (RUBY) Investor Presentation - Slideshow
Seeking Alpha - Article · 05/11 18:52
Rubius Therapeutics EPS misses by $0.04
Rubius Therapeutics (NASDAQ:RUBY): Q1 GAAP EPS of -$0.60 misses by $0.04. Cash, equivalents and investments of $241.39M (-14.8% Q/Q) Press Release
seekingalpha · 05/11 17:04
Rubius Therapeutics Q1 EPS $(0.60) Misses $(0.55) Estimate
Rubius Therapeutics (NASDAQ:RUBY) reported quarterly losses of $(0.600) per share which missed the analyst consensus estimate of $(0.550) by 9.09 percent. This is a 42.86 percent decrease over losses of $(0.420) per
Benzinga · 05/11 12:11

Industry

Biotechnology & Medical Research
+0.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About RUBY

Rubius Therapeutics Inc is a biotechnology company that develops cellular therapies for cancer, and enzyme deficiency diseases. The Company develops Red-Cell Therapeutics (RCT) products using red platform. RCT is a red blood cell-based therapy for applications in cancer, enzyme replacement therapies, and autoimmune disease and tolerance induction. Its RCT product candidate is designed to provide various attributes, which include broad therapeutic applications, predictable bio-distribution and advantageous tolerability. It is initially focused on advancing RCT product candidates for patients suffering from rare diseases, cancer and autoimmune diseases based on three modalities - cellular shielding, potent cell-cell interaction and tolerance induction. Its product candidates in rare diseases include RTX-134 for the treatment of phenylketonuria (PKU), RTX-134 followed by RTX-Uricase and RTX-CBS for the treatment of chronic refractory gout symptomatic homocystinuria.
More

Webull offers kinds of Rubius Therapeutics Inc stock information, including NASDAQ:RUBY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RUBY stock news, and many more online research tools to help you make informed decisions.